Novo Nordisk to issue Euro medium term notes worth up to EUR 5bn
On Friday, Denmark's largest pharmaceutical company announced the establishment of an EMTN program in which the company provides a framework for issuing unsecured notes worth billions of euros. The company states the proceeds will be put towards "general corporate purposes".
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN
The hunt for capital for general corporate purposes has led Novo Nordisk to establish a Euro Medium Term Note (EMTN) program through which it can issue unsecured notes up to an aggregated principal amount of EUR 5bn (USD 6.1m), according to a Friday press release from the firm.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
